Eli Lilly Expands Innovation with New Gateway Labs
Eli Lilly and Company (NYSE: LLY) has officially opened its latest Lilly Gateway Labs (LGL) facility, an exciting development aimed at strengthening the local biotechnology ecosystem. This new site, which covers an impressive 82,514 square feet, is designed to host up to 15 biotech companies, significantly contributing to the advancement of next-generation medical solutions.
A Collaborative Space for Biotech Startups
The Gateway Labs model offers a flexible laboratory environment that encourages collaboration and innovation. With Lilly's extensive resources and scientific expertise, early-stage biotech companies can navigate the complexities of drug discovery and development more effectively. The atmosphere fosters engagement, enabling budding scientists to thrive.
Location and Facilities
Located in a prominent biotech hub, the facility is part of the One Alexandria Square Megacampus in the renowned Torrey Pines area. This space is carefully designed to accommodate a wide range of life sciences companies and can support more than 250 employees from various startups using this facility.
Quote from Eli Lilly Executives
Daniel Skovronsky, M.D., Ph.D., chief scientific officer, emphasized, "At Lilly, we are committed to meeting the biotech ecosystem on its own terms, supporting companies at every stage and evolving alongside them. Our expanded presence here enables us to further connect with a vibrant startup community, promoting bold scientific discoveries. Through collaborative spaces like Lilly Gateway Labs, we're enabling bold science to thrive."
Facilitating Drug Discovery and Development
Lilly Gateway Labs provides not only state-of-the-art wet lab facilities but also strategic guidance tailored to the needs of early-stage biotechs. This unique approach integrates infrastructure with deep scientific knowledge, accelerating the progress towards achieving significant developmental milestones. The San Diego site becomes Lilly's fourth U.S. Gateway Labs location, joining existing facilities in South San Francisco and Boston, and also adds to a growing global network, with recent openings in locations such as Beijing.
Since the inception of Gateway Labs in 2019, participating companies have successfully secured over $2 billion in capital, leading to the development of more than 50 therapeutics and innovative platforms currently underway.
Continuous Support for Biotech Expansion
Julie Gilmore, Ph.D., vice president and global head of Lilly Gateway Labs, stated, "Our model is effective. By committing to a high-touch partnership approach, we start every engagement by asking how we can help. This mindset allows us to activate Lilly's extensive network to provide scientific insights and timely strategic counsel, ensuring startup founders avoid common pitfalls."
Diverse Therapeutic Areas at LGL San Diego
The innovating companies at Gateway Labs represent a diverse array of therapeutic approaches and target various diseases, aligning both with and extending beyond Lilly's core focus. The San Diego location has already drawn in several promising early-stage biotech companies looking to leverage next-generation modalities that aim to address complex medical challenges.
About Lilly Gateway Labs
Lilly Gateway Labs is a key initiative within Lilly's broader Catalyze360 program, which also encompasses Lilly Ventures, Lilly ExploR&D, and Lilly TuneLab. Together, they support biotech innovation by providing access to essential capital, advanced technology, and comprehensive research development capabilities, including cutting-edge AI tools.
About Eli Lilly and Company
At Eli Lilly, we are dedicated to transforming scientific insights into effective treatments to enhance lives globally. With nearly 150 years of experience, our life-changing medicines help millions. Our continued research spans critical areas such as diabetes management, obesity intervention, Alzheimer’s disease treatment, and innovative cancer therapies. We strive for diversity in clinical trials and work hard to ensure our therapies remain accessible and affordable for everyone. To explore more about us, please visit Lilly.com and follow us on our various social media platforms.
Frequently Asked Questions
What is the purpose of the Eli Lilly Gateway Labs?
The Eli Lilly Gateway Labs are designed to support early-stage biotech companies by providing them with laboratory space and access to scientific expertise, facilitating drug development.
How many biotech companies can the new San Diego facility accommodate?
The new Eli Lilly Gateway Labs facility in San Diego can accommodate up to 15 biotech companies.
What are the main advantages of being in the Gateway Labs?
Companies at Gateway Labs benefit from customized scientific engagement, laboratory amenities, and support in navigating the drug discovery process.
How has Lilly's Gateway Labs model performed since its inception?
Since launching in 2019, Lilly Gateway Labs has helped its companies raise over $2 billion, supporting the development of more than 50 therapeutic projects.
Where else does Lilly have Gateway Labs locations?
In addition to San Diego, Lilly Gateway Labs locations include sites in South San Francisco, Boston, and Beijing.
